


What is claimed is:

1. A compound of Formula I or a pharmaceutically acceptable salt thereof



wherein

- R^1 is selected from the group consisting of pyridinyl, 3-quinolinyl, thienyl, furanyl, C_{3-6} cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl, trifluoromethoxy and nitro;

A is $-CH=CH-$ or $-(CH_2)_n-$;

R^2 is C_{1-4} alkyl, CF_3 or hydroxymethyl;

R^3 , R^4 , R^5 and R^6 each are independently hydrogen or fluoro;

Z is oxygen or $-NR^7(CH_2)_m-$;


n is an integer of 0, 1, 2 or 3;

m is an integer of 0 or 1;

R^7 is hydrogen or C_{1-4} alkyl; and

B is pyridinyl, pyrimidinyl or pyrazinyl optionally substituted with a substituent selected from the group consisting of C_{1-4} alkyl, halogen, C_{1-4} alkoxy and trifluoromethyl.

2. The compound of claim 1 having the Formula Ic or a pharmaceutically acceptable salt thereof



wherein

R¹ is selected from the group consisting of pyridinyl, 3-quinolinyl, thienyl, furanyl, C₃₋₆ cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, trifluoromethoxy and nitro;

5 A is -CH=CH- or -(CH₂)_n;

R² is methyl or hydroxymethyl;

R³, R⁴, R⁵ and R⁶ each are independently hydrogen or fluoro;

Z is oxygen or -NR⁷(CH₂)_m;

n is an integer of 0, 1, 2 or 3;

10 m is an integer of 0 or 1;

R⁷ is hydrogen or C₁₋₄ alkyl; and

B is pyridinyl, pyrimidinyl or pyrazinyl optionally substituted with a substituent selected from the group consisting of C₁₋₄ alkyl, halogen, C₁₋₄ alkoxy and trifluoromethyl.

15

3. The compound of claim 1 selected from the group consisting of:

(S)-3-(2-fluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

(S)-3-(3-fluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

(S)-3-(4-fluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

20 (S)-3-(2,3-difluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

(S)-3-(2,4-difluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

(S)-3-(2,5-difluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-

25 acrylamide;

(S)-3-(2,6-difluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

(S)-3-(3,4-difluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

30 (S)-3-(3,5-difluoro-phenyl)-N-{1-[3-(pyridin-2-yloxy)-phenyl]-ethyl}-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-acrylamide;

- (*S*)-3-(3-fluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-acrylamide;
(*S*)-3-(4-fluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-acrylamide;
(*S*)-3-(2,3-difluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-acrylamide
(*S*)-3-(2,4-difluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-
5 acrylamide;
(*S*)-3-(2,5-difluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-
acrylamide;
(*S*)-3-(3,4-difluoro-phenyl)-N-{1-[3-(pyridin-3-yloxy)-phenyl]-ethyl}-
acrylamide;
10 (*S*)-3-(4-fluoro-phenyl)-N-{1-[3-(6-methyl-pyridin-3-yloxy)-phenyl]-ethyl}-
acrylamide;
(*S*)-3-(2,4-difluoro-phenyl)-N-{1-[3-(6-methyl-pyridin-3-yloxy)-phenyl]-ethyl}-
acrylamide;
(*S*)-3-(2,5-difluoro-phenyl)-N-{1-[3-(6-methyl-pyridin-3-yloxy)-phenyl]-ethyl}-
15 acrylamide;
(*S*)-N-{1-[3-(6-methyl-pyridin-3-yloxy)-phenyl]-ethyl}-3-(2,4,5-trifluoro-
phenyl)-acrylamide;
(*S*)-3-(2-fluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-acrylamide;
(*S*)-3-(3-fluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-acrylamide;
20 (*S*)-3-(4-fluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-acrylamide;
(*S*)-3-(2,3-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-
acrylamide;
(*S*)-3-(2,4-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-
acrylamide;
25 (*S*)-3-(2,6-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-
acrylamide;
(*S*)-3-(2,5-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-
acrylamide;
(*S*)-3-(3,4-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-
30 acrylamide;
(*S*)-3-(3,5-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-
acrylamide;

- (*S*)-3-(2,4-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-propionamide;
- (*S*)-3-(3,4-difluoro-phenyl)-N-{1-[3-(pyridin-4-yloxy)-phenyl]-ethyl}-propionamide;
- 5 (*S*)-3-(2-fluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(3-fluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(4-fluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(2,3-difluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- 10 (*S*)-3-(2,4-difluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(2,6-difluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(3,5-difluoro-phenyl)-N-{1-[3-(pyrazin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- 15 (*S*)-3-(2,3-difluoro-phenyl)-N-{1-[3-(pyrimidin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(2,6-difluoro-phenyl)-N-{1-[3-(pyrimidin-2-yloxy)-phenyl]-ethyl}-acrylamide;
- 20 (*S*)-3-(2-fluoro-phenyl)-N-{1-[3-(pyrimidin-5-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(3-fluoro-phenyl)-N-{1-[3-(pyrimidin-5-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(4-fluoro-phenyl)-N-{1-[3-(pyrimidin-5-yloxy)-phenyl]-ethyl}-acrylamide;
- (*S*)-3-(2,4-difluoro-phenyl)-N-{1-[3-(pyrimidin-5-yloxy)-phenyl]-ethyl}-acrylamide;
- 25 (*S*)-N-[1-(3-benzylamino-phenyl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide;
- (*S*)-N-[1-(3-benzylamino-phenyl)-ethyl]-3-phenyl-acrylamide;
- (*S*)-N-[1-(3-benzylamino-phenyl)-ethyl]-3-(2,4-difluoro-phenyl)-acrylamide; and
- (*S*)-N-[1-(3-benzylamino-phenyl)-ethyl]-3-(2,6-difluoro-phenyl)-acrylamide;
- or a pharmaceutically acceptable salt thereof.

30

4. A pharmaceutical composition for the treatment of disorders responsive to opening of KCNQ potassium channels comprising a therapeutically effective

amount of the compound of claim 1 in association with a pharmaceutically acceptable carrier, adjuvant or diluent.

5. A method for the treatment of disorders responsive to opening of the
5 KCNQ potassium channels in a mammal in need thereof, which comprises administering to said mammal a therapeutically effective amount of the compound of claim 1.
6. The method of claims 5 wherein said disorders are acute and chronic pain,
10 migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders.
7. The method of claim 6 wherein said disorder is migraine.
- 15 8. The method of claim 6 wherein said disorder is neuropathic pain.